This study will test the tolerability and effectiveness of SOL-GEL into the nose as a new way of administering a common MRI contrast agent.

For this study we are looking for approximately 12 healthy participants of any sex, race or ethnicity between the ages of 18 and 55 years.

The study is starting screening for healthy volunteers the week beginning 14th November, and will continue through to late-December 2022. 

Participation involves up to two visits and two follow-up phone calls. First is a Screening Visit at UQCCR, then eligible participants are randomised into either Stage 1 or 2:

• Stage 1, takes place at the University of Queensland Centre for Clinical Research (UQCCR), where participants receive a single dose of placebo (inactive) medication sprayed into each nostril and do not undergo MRI scans.

• Stage 2, takes place at the Centre for Advanced Imaging St Lucia campus, where participants receive a single dose of the experimental product sprayed into each nostril and undergo a series of MRI scans.

Eligibility 

  • Healthy Volunteers, males and females, aged 18 to 55 years old
  • BMI > 18.0 and < 32.0 kg/m2
  • Can have an MRI scan
  • No cosmetic tattoos (e.g. microblading)

Participant benefits

Participants will receive up to $500 to reimburse for their time.

Register your interest

To register your interest please leave your name, phone number and email address details when contacting the study team below:

  • Study Coordinator Dr. Roberta Littleford on (07) 3346 5046; r.littleford@uq.edu.au
  • Clinical Research Nurse Bernadette Rickards (07) 3346 5060; b.rickards@uq.edu.au

This study has been ratified by The University of Queensland Human Research Ethics Committee [Approval No. 2022/HE002004]